Sandoz Group AG | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Sandoz Group AG

BRIEF

published on 12/01/2025 at 07:05, 3 days 22 hours ago

Sandoz Launches Denosumab Biosimilars in Europe

Bone Health Sandoz Denosumab Biosimilars Wyost® Jubbonti®
PRESS RELEASE

published on 12/01/2025 at 07:00, 3 days 22 hours ago

Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment options for cancer-related bone disease and osteoporosis. The European launch marks a key milestone in Sandoz's growth strategy

Europe Biosimilars Cancer Osteoporosis Sandoz
BRIEF

published on 11/24/2025 at 07:05, 10 days 22 hours ago

Sandoz Launches Afqlir® in Europe for Retinal Diseases

Biosimilars Retinal Diseases Sandoz Europe Launch Afqlir®
PRESS RELEASE

published on 11/24/2025 at 07:00, 10 days 22 hours ago

Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases. Afqlir® matches reference medicine in efficacy, safety, and pharmacokinetics, reinforcing Sandoz commitment to patient access

Retinal Diseases Sandoz Aflibercept Afqlir European Launch
BRIEF

published on 11/17/2025 at 07:05, 17 days 22 hours ago

Sandoz Launches First MS Biosimilar TYRUKO® in US

Multiple Sclerosis Biosimilar Sandoz TYRUKO® Natalizumab
PRESS RELEASE

published on 11/17/2025 at 07:00, 17 days 22 hours ago

Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz launches TYRUKO® (natalizumab-sztn) in US, the first and only multiple sclerosis biosimilar, offering cost-effective treatment. TYRUKO® approved for all indications of reference medicine Tysabri®

US Market Multiple Sclerosis Biosimilar Sandoz TYRUKO
BRIEF

published on 11/12/2025 at 07:40, 22 days 21 hours ago

Sandoz Secures Global License for Breast Cancer Biosimilar

Oncology Biosimilar Breast Cancer Sandoz Pertuzumab
PRESS RELEASE

published on 11/12/2025 at 07:35, 22 days 21 hours ago

Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz signs global license agreement with EirGenix Inc. to commercialize biosimilar pertuzumab for HER2-positive breast cancer treatment, reinforcing its position in oncology

Agreement Biosimilar Breast Cancer Sandoz Pertuzumab
BRIEF

published on 11/04/2025 at 22:10, 1 month ago

Sandoz Acquires Just-Evotec Biologics to Expand Biosimilars Capabilities

Acquisition Biosimilars Toulouse Sandoz Just-Evotec
PRESS RELEASE

published on 11/04/2025 at 22:05, 1 month ago

Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz strengthens biosimilars capabilities with acquisition of Just-Evotec Biologics EU SAS in Toulouse. Acquisition aims to capture projected biosimilar market opportunity. Transaction includes cash payment and technology license fees

Acquisition Biosimilars Sandoz Just-Evotec Biologics Continuous Manufacturing Technology

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 45 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 50 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 20 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 15 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 20 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 50 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 29 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 55 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 5 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 10 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 20 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 35 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 36 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 19 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE